McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin E. Noonan authored an article entitled, “Global Biologic Drug Development and the TTP” that appears in the online edition of PharmExec.com on January 25, 2016. The diplomats negotiating the Trans-Pacific Partnership (TPP) agreement did the seemingly impossible: they kept the details of the draft agreement secret from the press and public in the US, Canada, Mexico, Australia, Singapore, Malaysia, Japan, Chile, Peru, Vietnam, New Zealand, and Brunei Darussalam (as well as the rest of the world) for over six years of deliberations until those details were released in early November. Some of the most controversial provisions of the TPP relate to exclusivities for pharmaceutical compounds, and in particular biosimilars (i.e., generic versions of biologic drugs) provided by the treaty. View the article